W. R. Berkley
WRB
$67.47
-1.13%
W.R. Berkley Corporation is a diversified insurance holding company that primarily underwrites commercial casualty insurance through a host of subsidiaries. The firm has established a distinct competitive identity as a specialist in niche products, including excess and surplus lines, workers' compensation, self-insurance consulting, and reinsurance, serving small to midsize businesses. The current investor narrative centers on the company's performance within a hardening insurance market, with attention focused on its ability to maintain underwriting discipline and achieve profitable growth amidst economic uncertainty, as reflected in recent quarterly earnings trends and analyst ratings.…
WRB
W. R. Berkley
$67.47
Investment Opinion: Should I buy WRB Today?
Rating: Hold. The core thesis is that WRB represents a financially sound company caught in a profitability downcycle, trading at a reasonable but not compelling valuation, warranting a wait-and-see approach until margin trends clarify.
Supporting this view are four key data points: 1) The forward P/E of 13.75x is not demanding for a profitable insurer, 2) Trailing FCF of $3.43B and a D/E of 0.29 provide a solid floor, 3) The stock trades 16% below its 52-week high, reflecting known risks, and 4) Analyst sentiment is mixed but includes bullish targets, suggesting potential upside if conditions improve. However, the 477 bps gross margin decline and negative price momentum counterbalance these positives.
The thesis would upgrade to Buy on a sustained reversal in gross margin trends (back above 22%) coupled with a technical breakout above $72 resistance. It would downgrade to Sell on a confirmed break below the $63.68 support level or a further sequential decline in quarterly net income. Relative to its own history and based on current fundamentals, the stock appears fairly valued, neither offering a clear margin of safety nor trading at an excessive premium.
Sign up to view all
WRB 12-Month Price Forecast
The outlook for WRB is one of stabilization at depressed levels rather than imminent recovery. The company's exceptional financial strength acts as a powerful buffer, making a catastrophic decline unlikely. However, the clear deterioration in core profitability (gross margin) must be arrested before a sustainable bullish thesis can be built. The base case of range-bound trading is most probable, as the market needs to see concrete evidence of margin improvement in upcoming quarterly reports. The stance would upgrade to bullish on two consecutive quarters of sequential gross margin expansion. It would turn bearish on a breakdown below $63.68 on elevated volume, signaling the fundamental deterioration is accelerating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on W. R. Berkley's 12-month outlook, with a consensus price target around $87.71 and implied upside of +30.0% versus the current price.
Average Target
$87.71
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$54 - $88
Analyst target range
Analyst coverage appears limited, with only 3 analysts providing estimates for revenue and EPS, suggesting this may be a less-followed name among institutional investors, which can contribute to higher volatility. The available data shows estimated EPS for the upcoming period ranging from $5.12 to $5.20, with an average of $5.17, and estimated revenue averaging $14.04 billion, indicating analysts expect steady performance. Recent institutional ratings from early 2026 show a mixed but generally neutral-to-positive sentiment, with firms like Cantor Fitzgerald and Argus Research maintaining 'Overweight'/'Buy' ratings, while others like Wells Fargo and Mizuho have 'Equal Weight'/'Neutral' stances, and one firm (TD Cowen) downgraded to 'Sell' in January, reflecting divergent views on the stock's near-term prospects.
Bulls vs Bears: WRB Investment Factors
The evidence presents a classic battle between value and momentum. The bull case is anchored in WRB's undeniable financial strength, attractive valuation, and defensive characteristics. The bear case is driven by clear technical weakness, deteriorating profitability metrics, and stagnant growth. Currently, the bearish evidence from price action and margin trends appears stronger in the near term, overshadowing the fundamental value. The single most important tension in the investment debate is whether the company's robust balance sheet and cash flow generation can successfully navigate and reverse the current pressures of gross margin compression before the stock re-tests its 52-week lows.
Bullish
- Exceptional Financial Health & Cash Flow: The company boasts a fortress balance sheet with a low debt-to-equity ratio of 0.29 and a healthy current ratio of 1.39. Most impressively, it generated $3.43 billion in trailing twelve-month free cash flow, providing immense flexibility for shareholder returns and strategic investments.
- Attractive Valuation Relative to Earnings: Trading at a forward P/E of 13.75x and a trailing P/E of 15.63x, WRB is valued at a discount to its own recent high of 18.17x. This mid-range valuation, combined with a 12.1% net margin, suggests the market is not pricing in significant future growth, offering a margin of safety.
- Strong Profitability and Underlying ROE: Despite recent margin compression, the company maintains solid profitability with a trailing net margin of 12.1% and a robust Return on Equity of 18.34%. This indicates efficient use of shareholder capital and the ability to generate earnings even in a challenging environment.
- Defensive Profile with Low Market Beta: With a beta of 0.33, WRB is approximately 67% less volatile than the broader market. This characteristic makes it a defensive holding, potentially offering downside protection during market downturns, as evidenced by its -8.6% 1-year return versus the S&P 500's +25.19% gain.
Bearish
- Pronounced Technical Downtrend: The stock is in a clear downtrend, down 13.70% over 6 months and 8.60% over 1 year, significantly underperforming the market. Trading at $66.45, it is only 18% above its 52-week low of $63.68, indicating persistent selling pressure and a lack of positive momentum.
- Significant Gross Margin Compression: Gross margin has contracted sharply from 25.25% in Q4 2024 to 20.58% in Q4 2025. This 477 basis point decline signals rising claims costs, competitive pricing pressure, or a less favorable business mix, directly threatening the core underwriting profitability of the insurance model.
- Stagnant Revenue Growth Trajectory: Revenue growth is anemic, with Q4 2025 revenue of $3.72 billion representing only a 1.4% year-over-year increase. Furthermore, sequential revenue declined from $3.77 billion in Q3 2025, raising questions about the company's ability to achieve top-line expansion in the current cycle.
- High PEG Ratio Suggests Overvaluation for Growth: The PEG ratio of 7.63 is extremely high, indicating that if the market prices the stock based on earnings growth expectations, it is very expensive. This metric highlights the tension between its reasonable P/E and its very low implied growth rate.
WRB Technical Analysis
The stock is in a pronounced downtrend, evidenced by a 1-year price change of -8.60% and a 6-month decline of -13.70%. Currently trading at $66.45, the price sits approximately 18% above its 52-week low of $63.68 and 16% below its 52-week high of $78.96, positioning it in the lower third of its annual range, which suggests a potential value opportunity but also indicates persistent selling pressure. Recent momentum shows a slight divergence, with a modest 1-month gain of 0.53% against a more significant 3-month loss of -4.66%, hinting at a possible stabilization or short-term consolidation after the steeper declines. The stock exhibits low market-correlated volatility, with a beta of 0.33, meaning it is roughly 67% less volatile than the broader market (SPY), which has implications for defensive positioning and lower relative risk. Key technical levels are clearly defined, with immediate support at the 52-week low of $63.68 and resistance near the recent highs around $78; a decisive break below support could signal a continuation of the downtrend, while a sustained move above $71-72 would be necessary to suggest a meaningful reversal.
Beta
0.33
0.33x market volatility
Max Drawdown
-17.8%
Largest decline past year
52-Week Range
$64-$79
Price range past year
Annual Return
-7.8%
Cumulative gain past year
| Period | WRB Return | S&P 500 |
|---|---|---|
| 1m | +3.2% | +5.5% |
| 3m | -5.1% | +7.7% |
| 6m | -13.6% | +12.7% |
| 1y | -7.8% | +27.4% |
| ytd | -2.7% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WRB Fundamental Analysis
Revenue growth has been modest but positive, with Q4 2025 revenue of $3.72 billion representing a 1.4% year-over-year increase; however, the multi-quarter trend shows some fluctuation, with revenue dipping from $3.77 billion in Q3 2025, indicating potential stabilization rather than robust expansion. The company remains solidly profitable, reporting Q4 2025 net income of $449.5 million and a trailing net margin of 12.1%; gross margin for the quarter was 20.58%, though it has compressed from 25.25% in Q4 2024, reflecting potential competitive or claims pressure in its insurance lines. Financial health is strong, supported by a robust balance sheet with a low debt-to-equity ratio of 0.29, a healthy current ratio of 1.39, and substantial cash generation evidenced by trailing twelve-month free cash flow of $3.43 billion, providing ample internal funding for operations, dividends, and share repurchases.
Quarterly Revenue
$3.7B
2025-12
Revenue YoY Growth
+0.01%
YoY Comparison
Gross Margin
+0.20%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WRB Overvalued?
Given the company's consistent profitability, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 15.63x and a forward PE of 13.75x; the lower forward multiple suggests the market anticipates modest earnings growth in the coming year. Compared to its own historical range, the current trailing PE of 15.63x is below the higher end seen in recent quarters (e.g., 18.17x in Q2 2025) but above the lows near 10.11x in Q4 2024, placing it in a mid-range valuation that does not signal extreme optimism or pessimism. While direct industry average multiples are not provided in the data, the stock's Price-to-Sales ratio of 1.89x and EV-to-Sales of 1.71x appear reasonable for a stable, cash-generative insurer, though the premium or discount relative to peers cannot be quantified without comparative sector data.
PE
15.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on profitability erosion rather than solvency. The sharp year-over-year gross margin compression from 25.25% to 20.58% is the most pressing concern, indicating the core underwriting engine may be under strain from higher claims or competitive pricing. While revenue growth is modest at 1.4% YoY, the sequential decline from Q3 to Q4 2025 suggests potential volatility or stabilization, limiting top-line catalysts. The high PEG ratio of 7.63 signals the market may be overpaying for minimal growth, creating valuation risk if earnings fail to re-accelerate.
Market & Competitive Risks are heightened by the stock's severe underperformance. WRB has a 1-year relative strength of -33.79% against the S&P 500, indicating a powerful sector or stock-specific rotation out of the name. Its low beta of 0.33, while defensive, also means it may not participate in market rallies, leading to continued opportunity cost. In a hardening insurance market, the inability to translate that into expanding margins (as seen) could signal a loss of competitive positioning or pricing power in its niche segments.
Worst-Case Scenario involves a continuation of the current downtrend fueled by a further earnings miss and guidance cut that confirms margin pressures are structural, not cyclical. This could trigger the remaining bullish analysts to downgrade, leading to a full derating. The realistic downside is a break below the 52-week low of $63.68, potentially extending to the $60 level, representing a loss of approximately 10-15% from the current price of $66.45. The historical max drawdown of -17.81% provides a benchmark for the potential depth of a sustained sell-off.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued gross margin compression, as seen in the 477 bps year-over-year decline, which directly erodes core profitability. 2) Price/Momentum Risk: The stock is in a pronounced downtrend (-13.7% over 6 months) and exhibits severe negative relative strength (-33.8% vs. SPY), indicating persistent selling pressure. 3) Growth Risk: Stagnant revenue growth (1.4% YoY) limits top-line catalysts and raises questions about market share. 4) Sentiment Risk: Limited analyst coverage (only 3 firms) can lead to higher volatility and inefficient price discovery, as seen in the recent mixed ratings including a 'Sell'.
The 12-month forecast is a range of scenarios with a base case target of $66-$72 (60% probability). The bull case ($75-$79, 25% probability) requires a halt to margin erosion and a market re-rating. The bear case ($60-$64, 15% probability) involves further earnings deterioration and a break of key support. The most likely scenario is range-bound trading, as the company's strong balance sheet prevents a collapse, but poor momentum and margin trends inhibit a sustained rally. The key assumption behind the base case is that gross margins stabilize near current levels of ~20.5% without further significant decline.
WRB appears fairly valued relative to its current fundamentals. Its forward P/E of 13.75x is below its own trailing P/E of 15.63x and its recent high of 18.17x, reflecting the market's discount for recent margin pressures. The high PEG ratio of 7.63 suggests it is expensive if valued on growth, but the low P/E suggests it is cheap if valued on stability. Compared to its own history and absent severe financial distress, the stock is not overvalued, but it is also not deeply undervalued enough to ignore the clear operational headwinds. The valuation implies the market expects low single-digit earnings growth at best.
WRB is a 'good buy' only for a specific type of investor: one seeking a defensive, financially-strong value stock and who has a patient, long-term horizon. The current 13.75x forward P/E is reasonable, and the 2.5% dividend yield is supported by massive free cash flow. However, the significant gross margin compression and clear downtrend make it a poor choice for short-term traders or growth investors. The biggest risk is further earnings degradation before the valuation becomes truly compelling. It could be a good buy on a further pullback towards the $63-$65 support zone for long-term holders.
WRB is unequivocally suitable for long-term investment, not short-term trading. Its low beta (0.33) means it lacks the volatility typically desired for short-term trades. As a cyclical financial stock, its turnaround depends on the multi-year underwriting cycle, which requires patience. The strong dividend and buyback potential are benefits that accrue over time. For a long-term investor willing to wait 3-5 years for the cycle to turn, WRB offers a quality franchise at a reasonable price. A minimum holding period of 18-24 months is suggested to potentially ride out the current downturn and benefit from a recovery.